Comparison of Domain Specificities of Inhibitors From Different Patient Groups
| . | Percentage of Plasmas Binding . | Patient Groups . | |||
|---|---|---|---|---|---|
| . | . | . | HA . | AA . | HA PUP . |
| A | 1 epitope region | A2, C2 or AR3-A3-C1 | 17 | 62 | 18 |
| ≥2 regions | Any combination | 57 | 29 | 45 | |
| ≥3 regions | A2 + C2 + AR3-A3-C1 | 26 | 10 | 36 | |
| B | A2 | Alone or in combination | 61 | 33 | 91 |
| C2 | Alone or in combination | 83 | 85 | 81 | |
| AR3-A3-C1 | Alone or in combination | 61 | 29 | 18 | |
| C | A2 + C2 | 17 | 5 | 45 | |
| C2 + AR3-A3-C1 | 35 | 19 | 0 | ||
| . | Percentage of Plasmas Binding . | Patient Groups . | |||
|---|---|---|---|---|---|
| . | . | . | HA . | AA . | HA PUP . |
| A | 1 epitope region | A2, C2 or AR3-A3-C1 | 17 | 62 | 18 |
| ≥2 regions | Any combination | 57 | 29 | 45 | |
| ≥3 regions | A2 + C2 + AR3-A3-C1 | 26 | 10 | 36 | |
| B | A2 | Alone or in combination | 61 | 33 | 91 |
| C2 | Alone or in combination | 83 | 85 | 81 | |
| AR3-A3-C1 | Alone or in combination | 61 | 29 | 18 | |
| C | A2 + C2 | 17 | 5 | 45 | |
| C2 + AR3-A3-C1 | 35 | 19 | 0 | ||
Inhibitor patient groups are as follows: HA, hemophilia A; AA, autoantibody; HA PUP, previously untreated hemophiliacs infused only with rfVIII. All numbers are percentages of the total plasmas tested: 23 for HA, 21 for AA, 11 for HA PUP. Section A: The % plasmas that contained a minimum of 1, 2, or 3 different inhibitor antibodies. Section B: The % plasmas containing antibodies with these specificities. Section C: The % plasmas with antibodies recognizing the combinations of epitope regions listed. The % inhibitors with specificity for 3 polypeptides occurred as A2 + C2 + AR3-A3-C1 only (section A) and is not included here.